Silo Pharma, Inc. (Nasdaq: SILO), a developmental stage biopharmaceutical company, announced that its Board of Directors has approved the purchase of up to $1 million in Bitcoin as a treasury reserve asset. This strategic decision aims to diversify the company's assets by incorporating a digital store of value, potentially offering significant upside. CEO Eric Weisblum explained that the move is intended to safeguard against inflation and enhance long-term shareholder value.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Silo Pharma Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9463875-en) on June 05, 2025, and is solely responsible for the information contained therein.